Dermot P.B. Mcgovern
Cedars-Sinai Medical Center
Appearances
- DateMay 7, 2023SOCIETY: AGA
Moderators
Katholieke Universiteit Leuven Universitaire Ziekenhuizen LeuvenCedars-Sinai Medical Center - DateMay 7, 2023The pathogenesis of inflammatory bowel disease (IBD) involves crosstalk between genetic and microbial factors that influence immune reactions. Tofacitinib, a pan JAK-STAT inhibitor, is a small molecule indicated for the treatment of moderate-to-severe ulcerative colitis (UC)…
Presenter
Cedars-Sinai Medical CenterSpeakers
Cedars-Sinai Medical Center - DateMay 8, 2023BACKGROUND: Mesenteric fat is increasingly believed to exert an important influence on intestinal inflammation. A hallmark of severe Crohn's disease (CD) is the accumulation of mesenteric fat around the inflamed intestine, typically in the terminal ileum…
Presenter
Speakers
Cedars-Sinai Medical Center - DateMay 9, 2023INTRODUCTION: We aimed to investigate the relationship between consumption of ultra-processed foods (UPFs) and: 1) active symptomatic disease and 2) intestinal inflammation in a cohort of adults living with inflammatory bowel disease (IBD)…
Presenter
Speakers
Cedars-Sinai Medical CenterCedars-Sinai Medical Center - DateMay 9, 2023INTRODUCTION: We aimed to investigate the relationship between consumption of ultra-processed foods (UPFs) and: 1) active symptomatic disease and 2) intestinal inflammation in a cohort of adults living with inflammatory bowel disease (IBD)…
Presenter
Speakers
Cedars-Sinai Medical CenterEmory UniversityUniversity of Miami Miller School of MedicineCedars-Sinai Medical CenterCedars-Sinai Medical Center - DateMay 9, 2023BACKGROUND: Cancer is a major cause of morbidity and mortality in persons with inflammatory bowel disease (IBD). We evaluated temporal trends and relative risks of intestinal and extra-intestinal cancers among persons with IBD and matched controls…
Presenter
Speakers
Cedars-Sinai Medical CenterCedars-Sinai Medical CenterCedars-Sinai Medical Center - DateMay 7, 2023Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Presenter
Speakers
University of Chicago Division of the Biological SciencesWestern UniversityCedars-Sinai Medical Center - DateMay 9, 2023SOCIETY: AGA
Moderators
Sinai Health SystemCedars-Sinai Medical Center - DateMay 18, 2024SOCIETY: AGA With the expansion of IBD treatment options, there is increasingly the need for predictive models to determine which treatments work best for which patients with IBD…
Moderators
Cincinnati Children’s Hospital Medical CenterCedars-Sinai Medical CenterSpeakers
Katholieke Universiteit Leuven Universitaire Ziekenhuizen LeuvenNorthwestern University Feinberg School of MedicineUniversity Hospitals Leuven - DateMay 19, 2024BACKGROUND: Although incidence of Inflammatory Bowel Disease (IBD) is rising in underrepresented populations, including Hispanics, genetic studies of IBD have primarily focused on Northern European ancestral populations…
Presenter
Speakers
Cedars-Sinai Medical CenterCedars-Sinai Medical CenterUniversity of Miami Miller School of MedicineIcahn School of Medicine at Mount SinaiCedars-Sinai Medical Center - DateMay 19, 2024BACKGROUND: With the comprehensive characterization of 14,287 primary genetic association with 2,923 plasma proteins in 54,219 UKBB participants, the recently published UKBB pQTL dataset provides a rich resource to elucidate the biological mechanisms underlying proteo-genomic discoveries and accele…
Presenter
Cedars-Sinai Medical CenterSpeaker
Cedars-Sinai Medical Center - DateMay 19, 2024Genetic and environmental influences contribute to Crohn’s disease (CD) development. However, the relationship between these two factors is unclear, limiting insights into CD pathophysiology, as well as interventions to prevent disease…
Presenter
Rutgers Robert Wood Johnson Medical SchoolSpeakers
Cedars-Sinai Medical CenterCedars-Sinai Medical Center INCIDENCE AND PREVALENCE OF INFLAMMATORY BOWEL DISEASES IN HISPANICS IN THE UNITED STATES, 2011-2020
DateMay 19, 2024BACKGROUND & AIMS: Hispanics account for 19% (62 million) of the US population, of whom 2/3rd are US born; with global and regional immigration patterns, Hispanics are expected to increase to 30% of the US population (111 million) by 2060…Presenter
University of California San DiegoSpeakers
- DateMay 18, 2024BACKGROUND: Previously we identified that patients with initial diagnosis of Ulcerative Colitis (UC) but subsequently had a diagnosis change to Crohn’s Disease (CD) (UC2CD) are a unique IBD subgroup with distinct serological, genetic and clinical features, including non-response to anti-TNF treatme…
Presenter
Cedars-Sinai Medical CenterSpeakers
- DateMay 18, 2024Background: _LRRK2_ variants (G2019S/N2081D) that increase Parkinson’s disease (PD) and Crohn’s Disease (CD) susceptibility are associated with LRRK2 kinase hyperactivity and suppress autophagy, suggesting that LRRK2 kinase inhibition, a strategy being explored for PD treatment, may also benefit CD…
Speakers
Cedars-Sinai Medical CenterPresenter